What is the appropriate use and safety profile of Glumasetide (generic name not specified) for gastrointestinal conditions in adults?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 1, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Glumasetide: Clarification of Identity and Clinical Use

Glumasetide is not a recognized medication name in current medical literature or FDA-approved drug databases; the term appears to be either a misspelling or confusion with glipizide, an established sulfonylurea medication for type 2 diabetes.

Actual Medication: Glipizide

Based on the FDA drug label provided, the medication in question is glipizide, a sulfonylurea used for glycemic control in type 2 diabetes 1.

Approved Indications

  • Type 2 diabetes mellitus as an adjunct to diet and exercise for blood glucose control 1
  • Not indicated for type 1 diabetes or diabetic ketoacidosis 1

Dosing Protocol

  • Initial dose: 5 mg before breakfast (2.5 mg for geriatric patients or those with liver disease) 1
  • Timing: Administer approximately 30 minutes before meals to achieve greatest reduction in postprandial hyperglycemia 1
  • Titration: Increase by 2.5-5 mg increments with several days between adjustments 1
  • Maximum daily dose: 40 mg total, with doses above 15 mg divided before meals 1
  • Drug interaction: When coadministered with colesevelam, glipizide should be given at least 4 hours prior 1

Adverse Event Profile

The most common adverse reactions are gastrointestinal disturbances 1:

  • Nausea and diarrhea occur in approximately 1 in 70 patients 1
  • Constipation and gastralgia occur in approximately 1 in 100 patients 1
  • These effects are dose-related and may resolve with dose division or reduction 1

Serious but rare adverse events include 1:

  • Hypoglycemia (most significant risk)
  • Cholestatic jaundice (requires discontinuation)
  • Hematologic effects: leukopenia, agranulocytosis, thrombocytopenia, hemolytic anemia, aplastic anemia, pancytopenia
  • Hyponatremia and syndrome of inappropriate antidiuretic hormone (SIADH) secretion
  • Allergic skin reactions in approximately 1 in 70 patients

Critical Safety Considerations

  • Hypoglycemia risk: Particularly in elderly, debilitated, or malnourished patients, and those with renal or hepatic impairment; conservative dosing required 1
  • Cardiovascular disease: Unlike some other diabetes medications, glipizide does not have cardiovascular outcome data comparable to GLP-1 receptor agonists
  • Hepatic monitoring: Rare elevations in liver enzymes (SGOT, LDH, alkaline phosphatase) and cholestatic/hepatocellular liver injury have been reported 1

Distinction from GLP-1 Receptor Agonists

If the question intended to reference GLP-1 analogs (which have similar-sounding names like glepaglutide), these are entirely different medication classes:

Glepaglutide (GLP-2 Analog)

  • Indication: Short bowel syndrome, not diabetes 2
  • Mechanism: Long-acting glucagon-like peptide-2 analogue that improves intestinal absorption 2
  • Efficacy: Doses of 1 mg and 10 mg reduced mean fecal output by 592 g/day and 833 g/day respectively in patients with short bowel syndrome 2
  • Common adverse events: Stoma complications (72%), injection site reactions (61%), peripheral edema (56%), nausea and abdominal pain (44% each) 2

GLP-1 Receptor Agonists (Semaglutide, Liraglutide)

  • Indications: Type 2 diabetes and obesity management 3
  • Gastrointestinal tolerability: Concomitant metformin use does not increase gastrointestinal adverse events during GLP-1RA initiation 4
  • Administration: Oral semaglutide requires specific dosing conditions (empty stomach, limited water, 30-minute wait before eating) 3

Clinical Pitfalls to Avoid

  • Do not confuse glipizide with GLP-1 analogs: Glipizide is a sulfonylurea with hypoglycemia risk, while GLP-1 agonists have low hypoglycemia risk and promote weight loss 3
  • Monitor for secondary failure: Glipizide may lose effectiveness over time, requiring dose adjustment or alternative therapy 1
  • Avoid in patients requiring insulin for type 1 diabetes: Glipizide is only for type 2 diabetes 1
  • Conservative dosing in vulnerable populations: Elderly, hepatic/renal impairment patients require lower starting doses (2.5 mg) 1

References

Related Questions

In a 35-year-old patient with epigastric pain and signs of gastroesophageal reflux disease (GERD) who reports dark (coffee‑ground) emesis, should an abdominal CT scan be performed?
What is the appropriate management for a 37‑year‑old woman with gastro‑oesophageal reflux disease who is taking pantoprazole and famotidine?
How should I evaluate and manage a 61-year-old male with gastroesophageal reflux disease (GERD) on omeprazole, schizophrenia on quetiapine, who presents with a neck mass and has a strong family history of gastrointestinal cancers, including pancreatic cancer?
In an 84-year-old woman with normal laboratory values and a solitary kidney who has intermittent gastroesophageal reflux disease, is a daily dose of omeprazole 20 mg or an as‑needed dose of omeprazole 40 mg more appropriate?
For a 33-year-old patient who has been on oral semaglutide (Rybelsus) 9 mg daily for at least one year, can the injectable semaglutide (Ozempic) be initiated at a dose of 0.5 mg weekly?
I have a right-sided headache with blurry vision, what should I do?
Is inositol supplementation effective for a female patient of reproductive age with premenstrual dysphoric disorder (PMDD)?
What are the effects of cannabis use on fertility and reproductive health in individuals trying to conceive?
What is the appropriate use and dosage of atropine in a catheterization (cath) lab setting for a patient with bradycardia, considering their medical history, including heart disease, hypertension, and glaucoma?
What is the recommended dose of valacyclovir (Valtrex) for an adult patient with a history of recurrent herpes simplex virus (HSV) 1 and 2 infections?
Is changing from prednisone (corticosteroid) to Allegra (fexofenadine) and Benadryl (diphenhydramine) an appropriate treatment adjustment for a patient with hives who showed improvement after the medication change?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.